Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy

被引:27
|
作者
Heide, Timon [1 ]
Maurer, Angela [1 ]
Eipel, Monika [1 ]
Knoll, Katrin [1 ]
Geelvink, Mirja [1 ]
Veeck, Juergen [1 ]
Knuechel, Ruth [1 ]
van Essen, Julius [2 ]
Stoehr, Robert [3 ]
Hartmann, Arndt [3 ]
Altmueller, Janine [4 ,5 ]
Graham, Trevor A. [6 ]
Gaisa, Nadine T. [1 ]
机构
[1] Rhein Westfal TH Aachen, Inst Pathol, Pauweisstr 30, D-52074 Aachen, Germany
[2] Rhein Westfal TH Aachen, Univ Hosp, Dept Urol, Aachen, Germany
[3] Univ Erlangen Nuernberg, Inst Pathol, Erlangen, Germany
[4] Univ Cologne, CCG, Cologne, Germany
[5] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany
[6] Queen Mary Univ London, Barts & London Sch Med & Dent, Bans Canc Inst, London, England
来源
JOURNAL OF PATHOLOGY | 2019年 / 248卷 / 02期
基金
英国工程与自然科学研究理事会;
关键词
bladder cancer; phylogenetic analysis; tumour heterogeneity; tumour evolution; tumour phenotype; kataegis; TRANSITIONAL-CELL CARCINOMA; CLONAL EVOLUTION; FGFR3; MUTATIONS; COPY NUMBER; FRAMEWORK; INSIGHTS;
D O I
10.1002/path.5250
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We present an evolutionary analysis of the relative time of genetic events underlying tumorigenesis in human bladder cancers from 10 whole cystectomy specimens using multiregional whole-exome sequencing. We timed bladder cancer drivers, mutational signatures, ploidy and copy number alterations, provided evidence for kataegis and correlated alterations with tumour areas and histological phenotypes. We found that: (1) heterogeneous tumour areas/phenotypes had distinct driver mutations, (2) papillary-invasive tumours divided early into two parallel evolving branches and (3) parallel evolution of subclonal driver mutations occurred. APOBEC mutational signatures were found to be very early events, active in carcinoma in situ, and often remained a dominant source of mutations throughout tumour evolution. Genetic progression from carcinoma in situ followed driver mutations in NA13/FAT1, ZBTB7B or EP300/USP28/KMT2D. Our results point towards a more diverse mutational trajectory of bladder tumorigenesis and underpin the importance of timing of mutational processes and clonal architecture in bladder cancer as important aspects for successful prognostication and therapy. Copyright (c) 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:230 / 242
页数:13
相关论文
共 50 条
  • [21] Distribution of photosensitizers in bladder cancer spheroids: Implications for intravesical instillation of photosensitizers for photodynamic therapy of bladder cancer
    Xiao, ZW
    Hansen, CB
    Allen, TM
    Miller, GG
    Moore, RB
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2005, 8 (03): : 536 - 543
  • [22] ACETYLATION PHENOTYPES AND BLADDER-CANCER
    HANKE, J
    KRAJEWSKA, B
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1990, 32 (09) : 917 - 918
  • [23] Therapy of Bladder Cancer
    Roth, Stephan
    AKTUELLE UROLOGIE, 2019, 50 (03) : 213 - 214
  • [24] Bladder Cancer and Cancer Stem Cells: Basic Science and Implications for Therapy
    Bryan, Richard T.
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 1187 - 1194
  • [25] Molecular Biology of Bladder Cancer Potential Implications for Therapy
    McConkey, David J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (03) : 457 - 468
  • [26] Comparison of whole exome sequencing and targeted sequencing in patients with advanced bladder cancer.
    Chawla, Neal Shiv
    Zengin, Zeynep
    Govindarajan, Ameish
    Pal, Sumanta K.
    CANCER RESEARCH, 2021, 81 (13)
  • [27] Folate-targeted therapy for invasive urinary bladder cancer
    Dhawan, Deepika
    Ramos-Vara, Jose
    Naughton, James
    Cheng, Liang
    Low, Phillip
    Rothenbuhler, Ryan
    Leamon, Christopher
    Parker, Nikki
    Klein, Patrick
    Vlahov, Iontcho
    Fourez, Lindsey
    Murphy, Linda
    Knapp, Deborah W.
    CANCER RESEARCH, 2012, 72
  • [28] Targeted agents in second-line bladder cancer therapy
    Gerullis, Holger
    Otto, Thomas
    Ecke, Thorsten H.
    ANTI-CANCER DRUGS, 2012, 23 (10) : 1003 - 1015
  • [29] Mechanisms of resistance to FGFR-targeted therapy in bladder cancer
    Pettitt, Geoffrey A.
    McPherson, Helen R.
    Hurst, Carolyn D.
    Burns, Julie E.
    Alder, Olivia A.
    Dunning, Matthew C.
    Knowles, Margaret A.
    CANCER RESEARCH, 2017, 77
  • [30] Disseminated tumour cells in bladder cancer
    Guzvic, Miodrag
    Engelmann, Simon
    Burger, Maximilian
    Mayr, Roman
    UROLOGIE, 2022, 61 (07): : 728 - 733